Evaluation of a digital tool supporting therapeutic decision making for the personalized management of patients with type 2 diabetes not treated with insulin: A pilot study

Aims: To investigate the benefits of using the Personalized Treatment Tool (PTT), a web-based clinical decision support tool assisting the diabetologist in the evaluation of patient's clinical characteristics and SMBG data, in the management of patients with non-insulin treated type 2 diabetes and inadequate glucose control.Methods: We conducted a single-center, 16-week, cluster-randomized controlled trial.Results: Eighty-two patients with 64.3 & PLUSMN; 9.4 years of age, disease duration 13.2 & PLUSMN; 9.1 years and HbA1c 7.8 & PLUSMN; 0.6%, 41 in the PTT group and 41 in the control group, completed the study. At follow-up, changes in indicators of glucose control and variability were not statistically different between the two groups. However, when considering the subgroup of patients on a single anti-diabetes drug at baseline (9 in the PTT group, 14 in the control group), changes in HbA1c and CGM-derived TIR 70-140 mg/dl, 24-hour MSG, GRADE, and HBGI were significantly improved in the PTT group compared to the control group.Conclusion: When performed in a structured manner and used to modify the diabetes therapy through an algorithm-driven digital tool, SMBG can lead to significant improvements of glycemic control and variability in patients with type 2 diabetes not treated with insulin.

Automated summary

The study investigates the benefits of using the Personalized Treatment Tool (PTT) in managing non-insulin treated type 2 diabetes patients. The PTT assists diabetologists in evaluating patients' clinical characteristics and self-monitoring blood glucose data. Results show significant improvements in glucose control and variability in patients using the PTT.